4.8 Article

FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors

Journal

CELL REPORTS
Volume 3, Issue 6, Pages 1766-1776

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2013.04.031

Keywords

-

Categories

Funding

  1. Leukaemia and Lymphoma Research Senior Bennett Fellowship
  2. Pasteur Institute of Iran
  3. Strategic Appointment and Programme grant from the Medical Research Council (UK)
  4. Hemato-Linne grant (Swedish Research Council Linnaeus)
  5. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust
  6. Fondation contre le cancer, Salus Sanguinis, Action de Recherche Concertee and Interuniversity Attraction Poles Programs and Fonds de la Recherche Scientifique, Belgium
  7. Ludwig Institute for Cancer Research
  8. MRC [MC_UU_12009/5, G84/6443, MC_UU_12009/7, G0900892, MC_UU_12009/11, G0801073, MC_PC_12020, G1000729, MC_U137961146, G0501838] Funding Source: UKRI
  9. Medical Research Council [G1000801c, MC_PC_12020, G0900892, G84/6443, G1000729, MC_UU_12009/5, MC_UU_12009/7, MC_U137961146, MC_UU_12009/11, G0501838, G0801073] Funding Source: researchfish

Ask authors/readers for more resources

Whether signals mediated via growth factor receptors (GFRs) might influence lineage fate in multipotent progenitors (MPPs) is unclear. We explored this issue in a mouse knockin model of gain-of-function Flt3-ITD mutation because FLT3-ITDs are paradoxically restricted to acute myeloid leukemia even though Flt3 primarily promotes lymphoid development during normal hematopoiesis. When expressed in MPPs, Flt3-ITD collaborated with Runx1 mutation to induce high-penetrance aggressive leukemias that were exclusively of the myeloid phenotype. Flt3-ITDs preferentially expanded MPPs with reduced lymphoid and increased myeloid transcriptional priming while compromising early B and T lymphopoiesis. Flt3-ITD-induced myeloid lineage bias involved upregulation of the transcription factor Pu.1, which is a direct target gene of Stat3, an aberrantly activated target of Flt3-ITDs, further establishing how lineage bias can be inflicted on MPPs through aberrant GFR signaling. Collectively, these findings provide new insights into how oncogenic mutations might subvert the normal process of lineage commitment and dictate the phenotype of resulting malignancies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Stephane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Joerg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Doehner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo

Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.

BLOOD (2023)

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Herve Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gokbuget, Jason Gotlib, Eva Hellstrom-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L. -C. Loh, Bob Lowenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Juergen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Dohner, Ayalew Tefferi

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

Review Hematology

Single-cell methods in myeloproliferative neoplasms: old questions, new technologies

Jennifer Mary O'Sullivan, Adam J. Mead, Bethan Psaila

Summary: Myeloproliferative neoplasms (MPN) are a group of hematopoietic malignancies driven by aberrant JAK/STAT signaling. Cellular heterogeneity at the single-cell level provides new insights into MPN biology, which can help predict clinical course and improve treatment strategies for these cancers, leading to better outcomes for patients.

BLOOD (2023)

Article Hematology

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Christian Pecquet, Nicolas Papadopoulos, Thomas Balligand, Ilyas Chachoua, Amandine Tisserand, Audrey Nedelec, Didier Vertommen, Anita Roy, Caroline Marty, Harini Nivarthi, Mira El-Khoury, Eva Hug, Andrea Majoros, Erica Xu, Oleh Zagrijtschuk, Tudor E. Fertig, Daciana S. Marta, Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, Ilaria Casetti, Elisa Rumi, Daniela Pietra, Chiara Cavalloni, Luca Arcaini, Mario Cazzola, Norio Komatsu, Yoshihiko Kihara, Yoshitaka Sunami, Yoko Edahiro, Marito Araki, Roman Lesyk, Veronika Buxhofer-Ausch, Sonja Heibl, Florence Pasquier, Violaine Havelange, Isabell Plo, William Vainchenker, Robert Kralovics, Stefan N. Constantinescu

Summary: Mutant CALR proteins bind to and activate the TpoR in cells, driving the development of myeloproliferative neoplasms. These mutant CALR proteins can be found in patient plasma complexed with sTFR1, which increases their stability. They can specifically interact with TpoR on target cells and promote thrombopoietin-independent colony formation.

BLOOD (2023)

Correction Oncology

Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients (Dec, 10.1038/s41375-022-01773-0, 2022)

Hosuk Ryou, Korsuk Sirinukunwattana, Alan Aberdeen, Gillian Grindstaff, Bernadette J. Stolz, Helen Byrne, Heather A. Harrington, Nikolaos Sousos, Anna L. Godfrey, Claire N. Harrison, Bethan Psaila, Adam J. Mead, Gabrielle Rees, Gareth D. H. Turner, Jens Rittscher, Daniel Royston

LEUKEMIA (2023)

Article Biochemistry & Molecular Biology

MARVEL: an integrated alternative splicing analysis platform for single-cell RNA sequencing data

Wei Xiong Wen, Adam J. Mead, Supat Thongjuea

Summary: A comprehensive R package called MARVEL was developed for single-cell splicing analysis. Extensive benchmarking and analysis of publicly available datasets demonstrated the importance and utility of MARVEL in single-cell research, enabling systematic analysis of splicing and gene expression to reveal biological insights.

NUCLEIC ACIDS RESEARCH (2023)

Article Oncology

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Marielle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Srdan Verstovsek, Natalia Curto-Garcia, Claire Harrison, Vikas Gupta

Summary: In patients with myelofibrosis who are naive to JAKi treatment, the rational combination of the BET inhibitor pelabresib and ruxolitinib showed good tolerability and durable improvements in spleen and symptom burden.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Cell Biology

Epigenetic programming defines haematopoietic stem cell fate restriction

Yiran Meng, Joana Carrelha, Roy Drissen, Xiying Ren, Bowen Zhang, Adriana Gambardella, Simona Valletta, Supat Thongjuea, Sten Eirik Jacobsen, Claus Nerlov

Summary: The lymphoid fate in haematopoietic stem cells is determined through epigenetic programming rather than transcriptional control, which also influences the differentiation pathways of platelets with distinct kinetics.

NATURE CELL BIOLOGY (2023)

Article Multidisciplinary Sciences

Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation

Nicolas Papadopoulos, Audrey Nedelec, Allison Derenne, Teodor Asvadur Sulea, Christian Pecquet, Ilyas Chachoua, Gaelle Vertenoeil, Thomas Tilmant, Andrei-Jose Petrescu, Gabriel Mazzucchelli, Bogdan I. Iorga, Didier Vertommen, Stefan N. Constantinescu

Summary: In myeloproliferative neoplasms, frameshift mutants of calreticulin turn into rogue cytokines by inducing constitutive activation of the Thrombopoietin Receptor (TpoR). Here, the authors define how mutant calreticulin acquires specificity for TpoR binding and triggers its constitutive activation.

NATURE COMMUNICATIONS (2023)

Article Hematology

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Sylvie D. Freeman, Abin Thomas, Ian Thomas, Robert K. Hills, Paresh Vyas, Amanda Gilkes, Marlen Metzner, Niels Asger Jakobsen, Alison Kennedy, Rachel Moore, Nuria Marquez Almuina, Sarah Burns, Sophie King, Georgia Andrew, Kathleen M. E. Gallagher, Rob S. Sellar, Paul Cahalin, Duruta Weber, Mike Dennis, Priyanka Mehta, Steven Knapper, Nigel H. Russell

Summary: Addition of gemtuzumab ozogamicin to induction chemotherapy improves outcomes in older AML patients, especially those with MRD<0.1% and IDH mutations. The survival advantage from this treatment is dependent on allogeneic transplantation.

BLOOD (2023)

Article Hematology

Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells

Sahoko Matsuoka, Raffaella Facchini, Tiago C. Luis, Joana Carrelha, Petter S. Woll, Takuo Mizukami, Bishan Wu, Hanane Boukarabila, Mario Buono, Ruggiero Norfo, Fumio Arai, Toshio Suda, Adam J. Mead, Claus Nerlov, Sten Eirik W. Jacobsen

Summary: This study investigates the critical regulatory role of hematopoietic stem cell (HSC) vascular niches in the bone marrow, particularly the expression of KIT ligand by endothelial niche cells. The findings suggest that both soluble and membrane-bound forms of endothelial-derived KIT ligand contribute to HSC regulation, but more specific tools are needed to understand the niche-specific roles of regulatory cues in hematopoietic niche cells.

BLOOD (2023)

Article Oncology

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Naval G. Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam S. Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N. Tanaka, Terrence J. Bradley, Deepa Jeyakumar, Eunice S. Wang, Kendra Sweet, Hagop M. Kantarjian, Guillermo Garcia-Manero, Rami Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F. Zeidner, David A. Sallman

Summary: Magrolimab combined with azacitidine showed promising efficacy and tolerability in patients with untreated AML ineligible for intensive chemotherapy, including those with TP53 mutations.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Multidisciplinary Sciences

Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner

Tiago C. Luis, Nikolaos Barkas, Joana Carrelha, Alice Giustacchini, Stefania Mazzi, Ruggiero Norfo, Bishan Wu, Affaf Aliouat, Jose A. Guerrero, Alba Rodriguez-Meira, Tiphaine Bouriez-Jones, Iain C. Macaulay, Maria Jasztal, Guangheng Zhu, Heyu Ni, Matthew J. Robson, Randy D. Blakely, Adam J. Mead, Claus Nerlov, Cedric Ghevaert, Sten Eirik W. Jacobsen

Summary: In this study, the researchers uncover a feedback mechanism in which IL-1 secreted by activated platelets signals through niche Lepr+ cells to activate HSCs and restore platelet homeostasis.

NATURE COMMUNICATIONS (2023)

Article Biotechnology & Applied Microbiology

Panhematopoietic RNA barcoding enables kinetic measurements of nucleate and anucleate lineages and the activation of myeloid clones following acute platelet depletion

Edyta E. Wojtowicz, Jayna J. Mistry, Vladimir Uzun, Charlotte Hellmich, Anita Scoones, Desmond W. Chin, Laura M. Kettyle, Francesca Grasso, Allegra M. Lord, David J. Wright, Graham J. Etherington, Petter S. Woll, Mirjam E. Belderbos, Kristian M. Bowles, Claus Nerlov, Wilfried Haerty, Leonid V. Bystrykh, Sten Eirik W. Jacobsen, Stuart A. Rushworth, Iain C. Macaulay

Summary: This study investigates the clonal dynamics of hematopoietic stem cells in the production of platelets and erythrocytes. The results show dynamic shifts of clonal behaviors over time and reveal that acute platelet depletion leads to exclusive production of platelets by multipotent hematopoietic stem cells. Additionally, the study identifies the emergence of new myeloid-biased clones supporting the production of blood cells.

GENOME BIOLOGY (2023)

Meeting Abstract Hematology

PARALLEL CLONAL AND MOLECULAR PROFILING OF HEMATOPOIETIC STEM CELLS USING RNA BARCODING

Edyta Wojtowicz, Jayna Mistry, Vladimir Uzun, Anita Scoones, Desmond Chin, Laura Kettyle, Allegra Lord, Francesca Grasso, Graham Etherington, Charlotte Hellmich, Petter Woll, Mirjam Belderbos, Kristian Bowles, Leonid Bystrykh, Claus Nerlov, Wilfried Haerty, Sten Eirik Jacobsen, Stuart Rushworth, Iain Macaulay

EXPERIMENTAL HEMATOLOGY (2022)

No Data Available